How do you decide whether to add docetaxel to ADT/abiraterone or ADT/darolutamide in patients with mCSPC in the era of PSMA PET staging?  

Given that PSMA PET often upstages patients, and conventional imaging defined "high volume" and "low volume" metastatic disease, how do you determine whether to escalate your treatment?